Mulberry Fruit Extract for Health & Longevity - Quick Reference Sheet

Mulberry Fruit Extract for Health & Longevity

Created on 10/15/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Mulberry fruit extract is a concentrated berry supplement from white and black mulberry trees used for mealtime blood sugar control and inflammation. Administered orally with starch or sugar meals, it blunts after-meal blood sugar and insulin spikes, though all extract trials come from one industry group. Evidence for blood fats, inflammation, blood pressure, and cognition is low and frequently conflicted, with gas emerging mainly at higher intakes. (Full Review)

Protocol

Postprandial glycemic protocol (1-DNJ-standardized extract)
0.37–0.75 g per carbohydrate meal
Standardized to ~0.5% 1-DNJ (1.85–3.75 mg 1-DNJ), mixed into or administered orally with the meal
Antioxidant and cardiometabolic protocol (anthocyanin-rich preparations)
300–1,000 mg/day extract or 20–100 g/day concentrate
Oral regimens targeting systemic inflammation, serum lipids, or cognition
Best time of day
First bite of the 1–2 highest-starch meals
Split dosing across carbohydrate meals for glycemic control; breakfast or lunch for anthocyanin supplementation
Time to effect
Postprandial Blood Glucose and Insulin Attenuation
30–120 minutes
Acute reduction in postprandial glucose and insulin excursions with the first mealtime dose
Serum Lipid and Apolipoprotein Modulation
6–8 weeks
Daily intake of concentrated fruit preparations for triglyceride and HDL-C shifts
Systemic Inflammation Reduction (C-Reactive Protein)
6–12 weeks
Daily oral supplementation for reductions in serum CRP and hs-CRP

Benefits

Contraindications
  • Individuals with known Moraceae or fig allergy
  • Pregnant or lactating women
  • Underweight or hypoglycemic individuals (BMI <18.5 kg/m² or fasting blood glucose <62 mg/dL [<3.4 mmol/L])
  • Active gastrointestinal dysfunction, malabsorption syndromes, or history of major gastrointestinal surgery
Key Interactions
  • Insulin and insulin secretagogues (glipizide, glimepiride, repaglinide, exogenous insulin)
  • Prescription alpha-glucosidase inhibitors (acarbose, miglitol, voglibose)
  • Non-secretagogue antidiabetic drugs: metformin, SGLT2 inhibitors (empagliflozin, dapagliflozin), and GLP-1 receptor agonists (semaglutide, liraglutide)
  • Narrow-therapeutic-index CYP3A4 and P-gp substrates (cyclosporine, tacrolimus, rivaroxaban, digoxin)
  • Over-the-counter medications: salicylates (aspirin), NSAIDs (ibuprofen, naproxen), and osmotic laxatives (polyethylene glycol, magnesium hydroxide)
  • Blood-glucose-lowering supplements (berberine, cinnamon, alpha-lipoic acid, gymnema, white mulberry leaf extract)
  • Other interventions (prolonged fasting and ketogenic diets)

Risk & Side Effects

  • High:
  • Medium: Carbohydrate malabsorption and flatulence at high doses
  • Low: Cross-reactive allergic reactions; severe gastrointestinal distress from excessive intake
  • Speculative: Additive hypoglycemia with antidiabetic therapy; altered bioavailability of CYP3A4 and P-glycoprotein substrates

Monitoring

Marker Target Why
2-Hour Postprandial Blood Glucose iAUC No established target; ≥20% reduction in 2-hour post-meal glucose iAUC from the individual's own baseline Efficacy marker: primary clinical outcome changed by MFE
Fasting Triglycerides <150 mg/dL (standard reference range) Efficacy marker: expected to decrease with daily concentrated fruit intake
High-Density Lipoprotein Cholesterol (HDL-C) >40 mg/dL in men, >50 mg/dL in women (standard reference range) Efficacy marker: expected to increase modestly over 8 weeks
High-Sensitivity C-Reactive Protein (hs-CRP) <3.0 mg/L (standard reference range) Efficacy marker: expected to decline with 6–8 weeks of supplementation
Fasting Blood Glucose 70–99 mg/dL (standard reference range) Safety check: screens against hypoglycemia (<70 mg/dL) if stacked with antidiabetic agents
Estimated Glomerular Filtration Rate (eGFR) ≥90 mL/min/1.73 m² (standard reference range) Safety check: verifies renal capacity to excrete absorbed 1-DNJ

Cadence: 1–2 week baseline before initiation; postprandial glucose excursions and gastrointestinal tolerance at weeks 1 and 4; fasting venous biomarkers (fasting blood glucose, triglycerides, HDL-C, hs-CRP, eGFR) at baseline, at 6–8 weeks, and every 6 months thereafter during sustained use (eGFR every 6–12 months).

Qualitative Assessment

  • Post-meal energy stability: Reduced postprandial drowsiness or afternoon fatigue following carbohydrate-heavy meals.
  • Gastrointestinal comfort: Absence of post-meal bloating, stomach rumbling, flatulence, or loose stools at the chosen dose.
  • Mucosal and skin tolerance: Absence of oral tingling, throat itching, or urticaria after dosing.